Bozkurt-Yozgatli, Tugce
Pehlivan, Davut
Gibbs, Richard A.
Sezerman, Ugur
Posey, Jennifer E.
Lupski, James R.
Coban-Akdemir, Zeynep
Article History
Received: 4 January 2024
Accepted: 27 March 2024
First Online: 16 April 2024
Declarations
:
: The study was approved by an institutional review board (IRB approval number: H-29697) at Baylor College of Medicine.
: All participants in the study gave written informed consent for participation and publication of clinical information.
: J.R.L. has stock ownership in 23andMe and is a paid consultant for Genomics International. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from molecular genetic and genomic testing offered at Baylor Genetics (BG) (ExternalRef removed). J.R.L. serves on the Scientific Advisory Board of BG. D.P. provides consulting service for Ionis Pharmaceuticals. The other authors declare no competing financial interests.